NCT00325013View on ClinicalTrials.gov

Evaluation of DHA for the Treatment of PSC

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Primary Sclerosing CholangitisColitis
Interventions
DRUG

Docosahexaenoic Acid (DHA)

800mg twice a day for 1 year

Trial Locations (2)

55905

Mayo Clinic, Rochester

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Beth Israel Deaconess Medical Center

OTHER

NCT00325013 - Evaluation of DHA for the Treatment of PSC | Biotech Hunter | Biotech Hunter